Gene therapy trial launches
A phase 1/2 clinical trial will launch this year to test a viral vector–based gene therapy for adults with type 1 diabetes — a push toward disease‑modifying approaches rather than glucose management alone (medscape.com). The study marks continued momentum in next‑generation treatments entering early human testing in 2026 (medscape.com).
Medscape reports a phase 1/2 trial of a novel viral‑vector gene therapy for adults with type 1 diabetes is scheduled to begin in 2026. (medscape.com (medscape.com)) Genprex is publicly advancing an AAV‑based candidate called GPX‑002 that delivers the transcription factors Pdx1 and MafA into the pancreas by endoscopic infusion into the pancreatic duct. (genprex.com (genprex.com)) Genprex reported preclinical proof‑of‑concept in nonhuman primates and mice showing restored or normalized blood glucose, higher C‑peptide, improved glucose tolerance and decreased insulin requirements after GPX‑002 administration. (PR Newswire (prnewswire.com)) The company says it has moved GPX‑002 manufacturing to contract development and manufacturing organizations and has requested (and sought FDA input on) IND‑enabling studies as part of preparations for first‑in‑human testing. (stocktitan.net SEC filing summary / PR Newswire (stocktitan.net) (prnewswire.com)) The Medscape story places this trial in the broader context of multiple next‑generation, disease‑modifying T1D approaches entering early human testing in 2026, alongside cell‑therapy and immunomodulatory programs highlighted at ATTD 2026. (medscape.com (medscape.com) attd.kenes.com (attd.kenes.com))
